相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITDAML
Amy Sexauer et al.
BLOOD (2012)
Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
Cheuk Him Man et al.
BLOOD (2012)
Ontogeny and Sorafenib Metabolism
Eric I. Zimmerman et al.
CLINICAL CANCER RESEARCH (2012)
CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
S. Negrotto et al.
LEUKEMIA (2012)
5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity
N. Curik et al.
LEUKEMIA (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Takashi Sato et al.
BLOOD (2011)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia
Aref Al-Kali et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
Gautam Borthakur et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype
Katharina Wagner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia
K. P. Ng et al.
LEUKEMIA (2011)
A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study
P. Chevallier et al.
LEUKEMIA (2011)
FLT3 as a therapeutic target in AML: still challenging after all these years
Thomas Kindler et al.
BLOOD (2010)
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse
Saiko Kurosawa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
K. W. Pratz et al.
LEUKEMIA (2010)
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
Farhad Ravandi et al.
LEUKEMIA RESEARCH (2010)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Stephan Metzelder et al.
BLOOD (2009)
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
Jianbiao Zhou et al.
BLOOD (2009)
Mutant FLT3:: A direct target of sorafenib in acute myelogenous leukemia
Weiguo Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway
W. Zhang et al.
LEUKEMIA (2008)
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways
Obdulio Piloto et al.
BLOOD (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Daniel J. DeAngelo et al.
BLOOD (2006)
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Mark Levis et al.
BLOOD (2006)
Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
HS Radomska et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Prognostic index for adult patients with acute myeloid leukemia in first relapse
DA Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression
R Zheng et al.
BLOOD (2004)
In vitro studies of a FM inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
M Levis et al.
BLOOD (2004)
Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A
M Milhem et al.
BLOOD (2004)
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith et al.
BLOOD (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations
M Mizuki et al.
BLOOD (2003)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia
T Pabst et al.
NATURE GENETICS (2001)
FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
F Hayakawa et al.
ONCOGENE (2000)